vs

Side-by-side financial comparison of Idaho Strategic Resources, Inc. (IDR) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.

Idaho Strategic Resources, Inc. is the larger business by last-quarter revenue ($14.6M vs $8.4M, roughly 1.7× Immunovant, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -899.0%, a 963.3% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 92.0%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-59.8M).

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

IDR vs IMVT — Head-to-Head

Bigger by revenue
IDR
IDR
1.7× larger
IDR
$14.6M
$8.4M
IMVT
Growing faster (revenue YoY)
IMVT
IMVT
+48.7% gap
IMVT
140.7%
92.0%
IDR
Higher net margin
IDR
IDR
963.3% more per $
IDR
64.3%
-899.0%
IMVT
More free cash flow
IDR
IDR
$68.0M more FCF
IDR
$8.2M
$-59.8M
IMVT

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
IDR
IDR
IMVT
IMVT
Revenue
$14.6M
$8.4M
Net Profit
$9.4M
$-75.3M
Gross Margin
68.5%
Operating Margin
62.4%
-896.2%
Net Margin
64.3%
-899.0%
Revenue YoY
92.0%
140.7%
Net Profit YoY
220.6%
-26.7%
EPS (diluted)
$0.62
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDR
IDR
IMVT
IMVT
Q4 25
$14.6M
Q3 25
$11.1M
Q2 25
$9.5M
Q1 25
$7.3M
Q4 24
$7.6M
Q3 24
$6.2M
Q2 24
$6.1M
Q1 24
$5.9M
$8.4M
Net Profit
IDR
IDR
IMVT
IMVT
Q4 25
$9.4M
Q3 25
$3.0M
Q2 25
$2.8M
Q1 25
$1.6M
Q4 24
$2.9M
Q3 24
$1.6M
Q2 24
$2.2M
Q1 24
$2.2M
$-75.3M
Gross Margin
IDR
IDR
IMVT
IMVT
Q4 25
68.5%
Q3 25
63.6%
Q2 25
57.8%
Q1 25
50.8%
Q4 24
53.3%
Q3 24
48.7%
Q2 24
50.2%
Q1 24
48.1%
Operating Margin
IDR
IDR
IMVT
IMVT
Q4 25
62.4%
Q3 25
23.4%
Q2 25
26.6%
Q1 25
19.3%
Q4 24
36.2%
Q3 24
23.4%
Q2 24
34.2%
Q1 24
36.3%
-896.2%
Net Margin
IDR
IDR
IMVT
IMVT
Q4 25
64.3%
Q3 25
26.8%
Q2 25
29.2%
Q1 25
22.1%
Q4 24
38.5%
Q3 24
25.8%
Q2 24
35.2%
Q1 24
36.8%
-899.0%
EPS (diluted)
IDR
IDR
IMVT
IMVT
Q4 25
$0.62
Q3 25
$0.20
Q2 25
$0.20
Q1 25
$0.12
Q4 24
$0.21
Q3 24
$0.12
Q2 24
$0.17
Q1 24
$0.17
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDR
IDR
IMVT
IMVT
Cash + ST InvestmentsLiquidity on hand
$635.4M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$108.2M
$617.8M
Total Assets
$116.2M
$666.4M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDR
IDR
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$6.3M
Q1 24
$5.3M
$635.4M
Total Debt
IDR
IDR
IMVT
IMVT
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
Q2 24
$2.7M
Q1 24
$3.3M
Stockholders' Equity
IDR
IDR
IMVT
IMVT
Q4 25
$108.2M
Q3 25
$74.3M
Q2 25
$49.3M
Q1 25
$39.8M
Q4 24
$37.7M
Q3 24
$33.1M
Q2 24
$25.4M
Q1 24
$21.6M
$617.8M
Total Assets
IDR
IDR
IMVT
IMVT
Q4 25
$116.2M
Q3 25
$83.1M
Q2 25
$57.7M
Q1 25
$48.1M
Q4 24
$44.0M
Q3 24
$40.8M
Q2 24
$32.2M
Q1 24
$28.7M
$666.4M
Debt / Equity
IDR
IDR
IMVT
IMVT
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDR
IDR
IMVT
IMVT
Operating Cash FlowLast quarter
$10.7M
$-59.7M
Free Cash FlowOCF − Capex
$8.2M
$-59.8M
FCF MarginFCF / Revenue
56.0%
-714.4%
Capex IntensityCapex / Revenue
17.7%
1.8%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$12.4M
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDR
IDR
IMVT
IMVT
Q4 25
$10.7M
Q3 25
$2.4M
Q2 25
$3.5M
Q1 25
$2.4M
Q4 24
$3.2M
Q3 24
$2.5M
Q2 24
$2.6M
Q1 24
$2.6M
$-59.7M
Free Cash Flow
IDR
IDR
IMVT
IMVT
Q4 25
$8.2M
Q3 25
$709.8K
Q2 25
$2.5M
Q1 25
$1.0M
Q4 24
$2.1M
Q3 24
$1.9M
Q2 24
$2.4M
Q1 24
$2.3M
$-59.8M
FCF Margin
IDR
IDR
IMVT
IMVT
Q4 25
56.0%
Q3 25
6.4%
Q2 25
26.5%
Q1 25
13.8%
Q4 24
28.0%
Q3 24
30.4%
Q2 24
38.7%
Q1 24
38.3%
-714.4%
Capex Intensity
IDR
IDR
IMVT
IMVT
Q4 25
17.7%
Q3 25
15.3%
Q2 25
10.8%
Q1 25
19.4%
Q4 24
13.6%
Q3 24
9.8%
Q2 24
4.3%
Q1 24
5.5%
1.8%
Cash Conversion
IDR
IDR
IMVT
IMVT
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons